During the rather hostile takeover engineered by Valeant Pharmaceuticals to acquire Allergan, charges were made by Allergan officials that Valeant was “a house of cards,” however no context was provided. A research report from Citron Research today offers context. In a report that is sending Valeant's stock tumbling, Citron claims Valeant is an Enron-like fraud. They offer as proof hidden corporate connections and undocumented demands for what appear as kickback payments from pharmacies that sell drugs to consumers.
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.
Do Hedge Funds Generate Alpha or Simply Provide Factor Exposure?
Q1 hedge fund letters, conference, scoops etc
This research note was originally published by the CAIA Association’s AllAboutAlpha blog. Here is the link.
SUMMARY
Diverse... Read More
Its been a big Herbalife Ltd. (NYSE:HLF) news week (or two), but its not over yet. As we first reported, Whitney Tilson had made the MLM company one of his... Read More
Quantitative Investment: Using The Language Of Numbers To Uncover Investment Opportunities by Balint Anton Francisc
Get The Timeless Reading eBook in PDF
Get the entire 10-part series on Timeless Reading in... Read More
Money Laundering Proving Tough Nut To Crack by Matthew Allen, SwissInfo.ch
Despite a focused international crackdown lasting several years, the BSI bank scandal shows that the dirty stains of money... Read More
The latest round in the never-ending saga between Carl Icahn and Marc Andreessen has Andreessen again referring to something Icahn did in the past. This time, he's taking us... Read More
Advisor Perspectives welcomes guest contributions. The views presented here do not necessarily represent those of Advisor Perspectives.
Q2 2020 hedge fund letters, conferences and more
Active nontransparent ETFs (ANTS) have frequently... Read More
Jeff Gundlach Ira Sohn coverage brought to you by ValueWalk.
Jeff Gundlach is Chief Executive Officer and Chief Investment Officer of DoubleLine. Jeff Gundlach was formerly associated with TCW where he was... Read More
Has value investing has been working as it worked before? The strategy that rewarded a great number of investors has been discussed recently. Buying stocks with the lowest valuations... Read More
Performance challenges in the global hedge fund industry continued in October, according to the latest eVestment hedge fund performance data. The industry’s aggregate performance of -3.10% for the month... Read More
I wanted to use the title “Leverage, Margin Calls, and Stock Prices, Oh My” here. But I decided to go with the more specific title so readers would actually... Read More
